NanoEntek Rises 6.31% Amid Uptrend in COVID-19 (Diagnosis/Treatment/Vaccine Development) Theme

On the 22nd, the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme rose by 3.17% compared to the previous day, showing strength, while NanoEnTek, which is attracting attention as a related stock, surged by 6.31% compared to the previous day. NanoEnTek is known as a nanobio specialized company.

[Graph] Major stock price changes in the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme



According to the analysis by Thinkpool Robo Algorithm RASSI, NanoEnTek ranked 5th (out of 47 stocks) in the quant financial ranking by exceeding the theme's average scores in growth, stability, and profitability. This can be interpreted as NanoEnTek having a relatively high investment attractiveness compared to other stocks within the theme from a financial perspective.

[Table] Top stocks by financial score within the theme


※ The quant financial score is the result of the Robo Algorithm's analysis based on each company's sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialized company Thinkpool.

This content was produced with the assistance of AI translation services.